Google
TVRD — TVARDI THERAPEUTICS, INC. (Healthcare >> Biotechnology)
TVRD FAQ
What is TVRD's P/E ratio?
TVARDI THERAPEUTICS, INC. (TVRD) currently trades at a P/E ratio of 6.64.
What is TVRD's ROE?
TVARDI THERAPEUTICS, INC. reports a Return on Equity (ROE) of -106.44%.
What is TVRD's dividend yield?
TVARDI THERAPEUTICS, INC. offers a dividend yield of 0.00%.
What is TVRD's Deepscope Quality Score?
Deepscope rates TVRD's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TVRD?
Deepscope's AI Timing Score for TVRD is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TVRD belong to?
TVARDI THERAPEUTICS, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.89
Price
-0.19
(-6.17%)
Day Change
|
|
|---|
TVRD, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 78 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.89 |
| PBV / Sector |
1.91 / 4.63
|
| Earning Per Share | -1.61 |
| PE / Sector |
6.64 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
0.09 / 0.53
GREAT
|
| Average 1M Daily Value |
0.18 M
GREAT
|
| Average 1W Daily Value |
0.18 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:30 |
| Symbol | TVRD |
| Name | TVARDI THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 9.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 27.67 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3 Sugar Creek Center Boulevard, Sugar Land, TX, United States, 77478
Phone: 713 489 8654
Website: https://tvarditherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
